For more information: Call 1-203-602-7777

New laboratory test accurately predicts risk of breast cancer relapse

• First test for personalized prognosis and relapse risk assessment using proteomics
• Guides post-operative adjuvant chemotherapy decision-making in early stage breast cancer, preventing over-treatment
• Achieves Level of Evidence 1 measuring uPA and PAI-1 proteins – recognized by international oncology organizations ASCO, EORTC, NACB as the most highly validated breast cancer biomarkers
• Currently in routine clinical use in Europe
  

Thank you for your interest in FEMTELLE.

• Your Name
  Prefix First Name Last Name
• Your Email Address*
• Your are:
  Health Professional Other Interest
• Your Questions
• Submit Form
• Should be Empty:

For Research Use Only
in the United States

View a bibliography of scientific publications and reviews.

ADI | Femtelle | Download PDF Brochure | Bibliography

American Diagnostica Inc. - Member of the Sekisui Group and a subsidiary of Sekisui Medical Co. Ltd., Tokyo, Japan